Goldman Sachs Maintains Buy on Syndax Pharmaceuticals, Raises Price Target to $34

Goldman Sachs analyst Corinne Johnson has maintained a Buy rating on Syndax Pharmaceuticals (NASDAQ: SNDX) and raised the price target from $28 to $34. This adjustment reflects a positive outlook for the company's stock performance.